Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

Author(s):

This discussion explores the occurrence and risk factors of neutropenia associated with SG treatment, comparing clinical practice experiences with trial data.

EP: 1.Overview of Current ADCs in Breast Cancer

EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components

Now Viewing

EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia

EP: 5.Navigating SG-related Diarrhea

EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea

EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd

EP: 9.Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

EP: 10.Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

EP: 11.Future Perspectives on ADCs in Breast Cancer

EP: 12.Expert Insights: Investigational ADCs Safety Profiles

EP: 13.Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

Let’s dive deeper into some of the specific adverse events that we may see with SG in our clinical practice….
How often do you see neutropenia in your clinical practice? How does it compare to the rates reported in clinical trials (ASCENT, TROPiCS-02)?
Are there risk factors that can help predict those who are at higher risk for developing neutropenia?